Division of Health Care Finance
Landon State Office Building
900 SW Jackson, Suite 900 N
Topeka, KS 66612-1220

Kansas Department of Health and Environment

Phone: 785-296-3981
Fax: 785-296-4813
www.kdheks.gov

Janet Stanek, Secretary

Laura Kelly, Governor

Drug Utilization Review Board Meeting
Agenda, Open Session April 19, 2023
10:00 a.m. – 2:00 p.m.

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:
Computer Audio Enabled Zoom Meeting:
https://us02web.zoom.us/j/87254963991?pwd=d2FQRW1XQ0plVngvNWx0TzRaNk9HZz09
Required Passcode: 799854 **Audio Dial in:** (312) 626-6799 US Toll-free
Meeting ID: 87254963991

Members of the general public are required to complete a conflict-of-interest (COI) form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (April 12, 2023). Please email the completed form to Annette.Grant@ks.gov.

COI Form: https://www.kdhe.ks.gov/DocumentCenter/View/15521/DUR-Conflict-of-Interest-Form-PDF

Board Members

Moneeshindra Mittal, MD (Chair)
James Backes, PharmD
Gregory Burger, PharmD, CPPS, FASHP, EMT
Daryl J. Callahan, D.O., M.S.S.
Jennifer Clair, MD
Cori Durall, PharmD
Kristen Powell, PharmD
Michele Reisinger, DNP, APRN, FNP-BC
Arthur Snow, MD

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, PharmD
Anh Rongish, PharmD, BCPS
Sridevi Donepudi, MD, MMM, FAAFP
Crystal Blackmon, Sr. Administrative Specialist

Gainwell Technologies/Kepro Staff

Karen Kluczykowski, RPh
Kathy Kaesewurm, RN, BSN
Harry Vu, PharmD
Debra Illions-Clark, LPN
Jordan Brazeal, PharmD

MCO Staff

Mark DeMary, PharmD – Aetna Better Health of Kansas
Angie Yoo, PharmD – Sunflower State Health Plan
Kelly Flannigan, PharmD – UnitedHealthcare Community Plan

I. CALL TO ORDER

A. Announcements

This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

II. OLD BUSINESS

A. Review and Approval of January 18, 2023 Meeting Minutes

III. NEW BUSINESS

A. Executive Sign-off – Re-evaluation of Process (6 Month Follow Up)

This agenda item pertains to the re-evaluation of the Executive Sign-off process, which was previously approved for six months at the October 2022 DUR meeting.

i. Review of Process
ii. *Public Comment
iii. Board Discussion

B. Executive Sign-off Agenda Items – Revised Prior Authorization (PA) Criteria

1. **Enzyme Replacement Therapy**
   This revision includes the migration of Strensiq® from its single-agent criteria and the addition of Lamzede® to the list of agents requiring prior authorization.

2. **Minimum Requirements Prior Authorization (MRPA)**
   This revision includes the migration of Luxturna® from its single-agent criteria and the addition of Givlaari® to the list of agents requiring prior authorization.

3. **Oncology Agents**
   This revision includes the removal of Cytalux®, the addition of multiple medications to the list of agents requiring prior authorization and updates a blanket statement regarding other FDA-approved indications.

i. Review of agenda items for Executive Sign-off
ii. Board Discussion

C. Revised Prior Authorization (PA) Criteria

1. **Axial Spondyloarthritis Agents** *(formerly Ankylosing Spondylitis (AS) Agents)*
   This revision includes revising the class' name, the re-evaluation of the treat-to-target strategy, and the addition of Amjevita™ to the list of agents requiring prior authorization.

i. Revised PA Criteria
ii. *Public Comment
iii. Board Discussion

2. **Diabetes Mellitus – Type 2 Agents**
   This revision includes clarification of the HbA1c requirements, removal of metformin step-therapy, and re-evaluation of the renewal criteria.

i. Revised PA Criteria
ii. *Public Comment
iii. Board Discussion

3. **Multiple Sclerosis (MS) Agents**
   This revision includes the addition of Briumvi™ and Tascenso ODT® to the list of agents requiring prior authorization, proposal of step-therapy, and updates a blanket statement regarding other FDA-approved indications.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

4. **Opioid Use Disorder (OUD) Agents**
   This revision includes the removal of the XDEA number requirement in observance of recent changes in federal statute. Other minor formatting and standard language updates are also included.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

5. **Alzheimer's Disease Agents** *(formerly Aduhelm)*
   Among other various revisions, this criteria expands the existing single agent PA to a class PA with the addition of Leqembi™ to the list of agents requiring prior authorization.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

6. **Adult Rheumatoid Arthritis (RA) Agents**
   This revision includes the addition of Amjevita™ to the list of agents requiring prior authorization and updates a blanket statement regarding other FDA-approved indications.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

7. **Crohn's Disease (CD) Agents**
   This revision includes the addition of Amjevita™ and Skyrizi® On-Body Injector prefilled cartridges to the list of agents requiring prior authorization.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

8. **Psoriatic Arthritis (PsA) Agents**
   This revision includes the addition of Amjevita™ to the list of agents requiring prior authorization, updates to indicated age for Stelara®, and updates a blanket statement regarding other FDA-approved indications.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

9. **Ulcerative Colitis (UC) Agents**
   This revision includes the addition of Amjevita™ to the list of agents requiring prior authorization, a minor clarification in the footnote of Table 1, and reorganization of the references.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

D. Tentative Agenda Items (MHMAC and PDL Meeting Agenda Items)

1. **PDL Meeting (January 17, 2023) – New PDL Classes**

   a. Sleep Agents - Scheduled - Orexin Receptor Antagonists: Belsomra®, Dayvigo®, Quviviq™

      i. Public Comment
      ii. Board Discussion

E. Miscellaneous Items

1. **Fee-for-Service Retrospective Drug Utilization Review Topic Selections**
   The DUR Board will select topics for the two (2) FFS RDUR interventions between May and June 2023.

      i. Presentation
      ii. Board Discussion

IV. ADJOURN

The next DUR Board meeting is scheduled for July 19, 2023.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE****